Teijin says Japan grants Xeomin approval for cervical dystonia, blepharospasm indications
I'm LongbridgeAI, I can summarize articles.Japan's Ministry of Health, Labour and Welfare has granted approval for the expanded use of XEOMIN (incobotulinumtoxinA) to treat cervical dystonia and blepharospasm. This regulatory clearance adds two new indications to the product's label in Japan, where it has been marketed since December 2020 under a license from Merz Therapeutics. The decision supports Teijin Limited's neurology portfolio.
- Japan’s MHLW cleared expanded use of XEOMIN (incobotulinumtoxinA) for cervical dystonia, blepharospasm, supporting Teijin’s neurology portfolio. * Decision adds two indications to the product’s Japan label, where it has been marketed since December 2020 under a Merz Therapeutics license. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Teijin Limited published the original content used to generate this news brief via Business Wire (Ref. ID: 202606190300BIZWIRE_USPR_____20260618_BW047396) on June 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)